切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2014, Vol. 08 ›› Issue (05) : 1 -5. doi: 10.3877/cma. j. issn.1674-0807.2014.05.001

专家论坛

2014 年《美国临床肿瘤学会临床实践指南:HER-2 阳性晚期乳腺癌系统治疗》解读
王佳玉1, 徐兵河1,()   
  1. 1.100021 北京,中国医学科学院北京协和医学院肿瘤医院内科
  • 收稿日期:2014-09-22 出版日期:2014-10-01
  • 通信作者: 徐兵河

Systemic therapy for patients with advanced HER-2 positive breast cancer: interpretation on 2014 ASCO clinical practice guideline

Jiayu Wang, Binghe Xu()   

  • Received:2014-09-22 Published:2014-10-01
  • Corresponding author: Binghe Xu
引用本文:

王佳玉, 徐兵河. 2014 年《美国临床肿瘤学会临床实践指南:HER-2 阳性晚期乳腺癌系统治疗》解读[J]. 中华乳腺病杂志(电子版), 2014, 08(05): 1-5.

Jiayu Wang, Binghe Xu. Systemic therapy for patients with advanced HER-2 positive breast cancer: interpretation on 2014 ASCO clinical practice guideline[J]. Chinese Journal of Breast Disease(Electronic Edition), 2014, 08(05): 1-5.

[1]
Members of the Breast Cancer Disease Site Group. The role of trastuzumab(Herceptin) in the treatment of women with HER2/neu-overexpressing metastatic breast cancer[EB/OL]. [2014-06-26].https:/ /www.cancercare.on.ca/pdf/pebc1-15f.pdf.
[2]
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med,2001,344(11):783-792.
[3]
Huober J, Fasching PA, Barsoum M, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancerresults of the eLEcTRA trial[J]. Breast,2012,21(1):27-33.
[4]
Schwartzberg LS,Franco SX,Florance A,et al. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptorpositive metastatic breast cancer [ J]. Oncologist, 2010,15(2):122-129.
[5]
Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase ⅢTAnDEM study[J]. J Clin Oncol,2009,27(33):5529-5537.
[6]
Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. N Engl J Med,2012,366(2):109-119.
[7]
Blackwell KL, Miles D, Gianni L, et al. Primary results from EMILIA, a phase Ⅲstudy of trastuzumab emtansine (T-DM1)versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane[EB/OL]. [2014-06-26]. http:/ /meetinglibrary.asco.org/content/98675-114.
[8]
Verma S, Miles D, Gianni L,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. N Engl J Med,2012,367(19):1783-1791.
[9]
Andersson M, Lidbrink E, Bjerre K, et al. Phase Ⅲrandomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer:the HERNATA study[J]. J Clin Oncol,2011,29(3):264-271.
[10]
Valero V, Forbes J, Pegram MD, et al. Multicenter phase Ⅲrandomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer ( BCIRG 007 study): two highly active therapeutic regimens[J]. J Clin Oncol,2011,29(2):149-156.
[11]
Inoue K, Nakagami K, Mizutani M, et al. Randomized phaseⅢtrial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group[J]. Breast Cancer Res Treat,2010,119(1):127-136.
[12]
Gelmon KA, Boyle F, Kaufman B, et al. Open-label phase Ⅲrandomizedcontrolledtrialcomparingtaxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2 + metastatic breast cancer: Interim analysis(IA) of NCIC CTG MA.31/GSK EGF 108919 [ EB/OL]. [2014-06-26]. http:/ /meetinglibrary.asco.org/content/102986-114.
[13]
Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer[J]. J Clin Oncol,2010,28(7):1124-1130.
[14]
Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study[J]. J Clin Oncol,2012,30(21):2585-2592.
[15]
Cameron D, Casey M, Oliva C, et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase Ⅲrandomized trial[J]. Oncologist,2010,15(9):924-934.
[16]
Cameron D, Casey M, Press M, et al. A phase Ⅲrandomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses[J].Breast Cancer Res Treat,2008,112(3):533-543.
[17]
von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study[J]. J Clin Oncol,2009,27(12):1999-2006.
[18]
von Minckwitz G, Vogel P, Schmidt M, et al. Trastuzumab treatment beyond progression in patients with HER-2 positive metastatic breast cancer: the TBP study (GBG 26 / BIG 3-05)[ EB/OL ]. [ 2014-06-26 ]. http:/ /www. freecme. net/journalclub/abstract_breastcancer/Abstract_4056.html.
[19]
von Minckwitz G, Zielinski C, Maarteense P, et al.Capecitabine vs. capecitabine trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase Ⅲstudy (GBG 26/BIG 3-05)[EB/OL]. [2014-06-26]. http:/ /meeting. ascopubs.org/cgi/content/abstract/26/15_suppl/1025.
[20]
Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression[J]. J Clin Oncol,2004,22(6):1063-1070.
[21]
Wildiers H, Kim SB, Gonzalez-Martin A, et al. T-DM1 for HER2-positive metastatic breast cancer ( MBC): Primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice[C]/ / The European Cancer Congress,Amsterdam, the Netherlands, September 27-October 1,2013.Amsterdam: European Cancer Congress,2013.
[22]
Swain SM, Kim SB, Cortes J, et al. Confirmatory overall survival (OS) analysis of CLEOPATRA: A randomized,double-blind, placebo controlled Phase Ⅲ study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC) [EB/OL]. [2014-06-26]. http:/ /cancerres. aacrjournals. org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/P5-18-26.
[23]
Maxwell C. Quality-of-life considerations with taxane-based therapy in metastatic breast cancer[J]. Clin J Oncol Nurs,2013,17 Suppl:35-40.
[24]
National Cancer Institute. Breast cancer treatment (PDQ):Stage ⅢB, inoperable ⅢC, Ⅳ, recurrent, and metastatic breast cancer—Ado-trastuzumab emtansine[EB/OL]. [2014-06-26]. http:/ /www. cancer. gov/cancertopics/pdq/treatment/breast/healthprofessional/page6.
[25]
Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy[J]. J Clin Oncol,2010,28(7):1138-1144.
[26]
O'Shaughnessy J, Blackwell KL, Burstein H, et aL. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2 + metastatic breast cancer progressing on trastuzumab therapy[EB/OL]. [2014-06-26]. http:/ /meeting. ascopubs. org/cgi/content/abstract/26/15_suppl/1015.
[27]
Esteva FJ, Valero V,Booser D,et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer[J]. J Clin Oncol,2002,20(7):1800-1808.
[28]
Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage Ⅳnon-small-cell lung cancer[J]. J Clin Oncol,2009,27(36):6251-6266.
[29]
Fagerlin A, Zikmund-Fisher BJ, Ubel PA. Helping patients decide: ten steps to better risk communication[J]. J Natl Cancer Inst,2011,103(19):1436-1443.
[30]
Butow PN, Dowsett S, Hagerty R, et al. Communicating prognosis to patients with metastatic disease:what do they really want to know? [J]. Support Care Cancer, 2002, 10(2):161-168.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[3] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[4] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[5] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[6] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[7] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[8] 王秋生. 胆道良性疾病诊疗策略[J]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 779-782.
[9] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[10] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[11] 魏志鸿, 刘建勇, 吴小雅, 杨芳, 吕立志, 江艺, 蔡秋程. 肝移植术后急性移植物抗宿主病的诊治(附四例报告)[J]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 846-851.
[12] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[13] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[14] 张平骥, 徐钰, 李天水, 庞文翼, 符师宁, 张梦圆. 重症患者镇静治疗现状及期望的调查研究[J]. 中华临床医师杂志(电子版), 2024, 18(06): 562-567.
[15] 王昌前, 林婷婷, 宁雨露, 王颖杰, 谭文勇. 光免疫治疗在肿瘤领域的临床应用新进展[J]. 中华临床医师杂志(电子版), 2024, 18(06): 575-583.
阅读次数
全文


摘要